Collegium Pharmaceutical (COLL) Stock Price, News & Analysis

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COLL shares.
View COLL analyst ratings or view top-rated stocks.

5 brokerages have issued 12 month price objectives for Collegium Pharmaceutical's stock. Their COLL share price targets range from $37.00 to $40.00. On average, they predict the company's share price to reach $39.00 in the next year. This suggests a possible upside of 11.9% from the stock's current price.
View analysts price targets for COLL or view top-rated stocks among Wall Street analysts.

Collegium Pharmaceutical's stock was trading at $30.78 at the beginning of the year. Since then, COLL shares have increased by 13.2% and is now trading at $34.84.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our COLL earnings forecast.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its quarterly earnings results on Thursday, February, 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.25. The specialty pharmaceutical company earned $149.75 million during the quarter, compared to analysts' expectations of $147.66 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 107.39% and a net margin of 8.50%.

ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), First Trust Dow Jones Select Microcap Index Fund (FDM), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Inspire Fidelis Multi Factor ETF (FDLS) and Pacer US Small Cap Cash Cows 100 ETF (CALF).

Collegium Pharmaceutical updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $583.5 million.

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

Collegium Pharmaceutical (COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.21%) and Allspring Global Investments Holdings LLC (0.14%). Insiders that own company stock include Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends.

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.